SHERIDAN, WYOMING – May 8, 2025 – PerkinElmer, a global leader in analytical solutions and specialized services for the bio-pharma, applied, and food markets, has announced its acquisition of Project Farma, a subsidiary of Precision for Medicine. The acquisition, which aims to enhance PerkinElmer's OneSource professional services business, strengthens its position as a critical partner for life sciences organizations looking to accelerate the delivery of innovative therapies.
Strategic Expansion to Support Life Sciences Innovation
The acquisition of Project Farma, a renowned life sciences consultancy, marks a significant milestone in PerkinElmer’s mission to empower customers throughout the value chain. The acquisition broadens OneSource’s lab solutions offering by integrating Project Farma’s extensive experience in advancing technical operations, from initial ideation through to commercialization.
"We are excited to welcome Project Farma’s highly skilled teams to PerkinElmer," said Dirk Bontridder, CEO of PerkinElmer. "This acquisition expands the professional services offering of OneSource, our market-leading lab solutions business, and creates an even stronger solution offering for life sciences customers throughout the value chain. The addition further accelerates our mission to empower customers in delivering innovative therapies to market with greater speed and efficiency.”
Project Farma has long been known for its work in supporting complex biologics, cell and gene therapies, radioligands, and other novel therapeutic modalities. With a proven track record in technical operations, Project Farma has helped its clients design, build, and scale Good Manufacturing Practices (GMP) facilities, manage large-scale capital projects, and provide crucial regulatory and quality compliance services.
Leveraging Global Expertise for Accelerated Drug Development
Project Farma was founded in 2016 with a focus on providing patient-centered, technical operations support for the life sciences industry. The consultancy has successfully executed over 100 facility builds and retrofits, managed more than 400 large-scale capital projects, and industrialized 10+ commercial cell and gene therapies. Project Farma’s team has managed upwards of $6 billion in technical operations capital investments, helping clients bring groundbreaking therapies to market more efficiently.
"Joining PerkinElmer’s OneSource business presents an incredible opportunity to accelerate our mission of advancing next-generation medicines," said Anshul Mangal, co-founder and CEO of Project Farma. "Leveraging PerkinElmer’s global customer portfolio and combining our expertise will enable us to provide even more comprehensive solutions to drug developers facing complex laboratory, manufacturing, and other technical challenges globally."
This strategic acquisition allows PerkinElmer to deliver even greater value to its customers by leveraging its broad global portfolio alongside Project Farma’s niche expertise in biologics and complex therapies. The combination of these capabilities is expected to streamline drug development processes and offer improved operational efficiency for life sciences organizations.
Strengthening PerkinElmer’s Commitment to Advancing Healthcare
PerkinElmer’s commitment to accelerating scientific breakthroughs and transforming global healthcare is further solidified by this acquisition. With a deep understanding of complex technical operations in life sciences, PerkinElmer aims to help clients scale their capabilities, reduce time-to-market for new therapies, and enhance the overall impact on public health.
Through its OneSource platform, PerkinElmer provides an array of solutions that help life sciences organizations meet regulatory demands, improve product quality, and streamline research and manufacturing workflows. The addition of Project Farma’s specialized services will only enhance these offerings, ensuring clients have the resources and support needed to drive innovation in drug development.
About PerkinElmer
Founded in 1937, PerkinElmer is a global leader in providing measurement, testing, and sample preparation solutions for customers in the bio-pharma, applied, and food markets. With a team of 5,000 experts operating in 35 countries, PerkinElmer accelerates scientific discoveries and amplifies customer impact to create a healthier, safer, and more sustainable world.
For more information, visit www.perkinelmer.com.
About Project Farma
Project Farma is a global leader in advancing technical operations for complex biologics and novel therapeutic modalities. With expertise in planning, building, and maintaining manufacturing facilities, the company has helped clients design, scale, and operate GMP facilities for groundbreaking therapies. Project Farma works with pharmaceutical companies, universities, hospitals, and government agencies to bring next-generation medicines to market.
For more information, visit www.projectfarma.com.